HALO
Halozyme Therapeutics
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: HALO
- PE Ratio
As of Jul 13, 2026, the HALO stock has a P/E ratio of 25.71. The calculation is based on the latest EPS of $2.96 and the stock price of $76.11 per share. An increase of 39% has been observed in the PE ratio compared to its average of 18.5 of the past four quarters.
HALO PE ratio history
The mean historical PE ratio of Halozyme Therapeutics over the last nine years is 28.98. The current 25.71 price-to-earnings ratio is 11% less than the historical average. Analyzing the last nine years, HALO's PE ratio reached its highest point in the Sep 2020 quarter at 146, with a price of $26.28 and an EPS of $0.18. The Jun 2025 quarter saw the lowest point at 11.61, with a price of $52.02 and an EPS of $4.48.
Halozyme Therapeutics PE ratio by year
Maximum annual increase: 173.47% in 2022
Maximum annual decrease: -68.73% in 2021
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 25.49 | 86.6% | $67.3 | $2.64 |
| 2024 | 13.66 | -21.27% | $47.81 | $3.5 |
| 2023 | 17.35 | -54.88% | $36.96 | $2.13 |
| 2022 | 38.45 | 173.47% | $56.9 | $1.48 |
| 2021 | 14.06 | -68.73% | $40.21 | $2.86 |
| 2020 | 44.96 | N/A | $42.71 | $0.95 |
| 2019 | N/A | N/A | $17.73 | -$0.5 |
| 2018 | N/A | N/A | $14.63 | -$0.56 |
| 2017 | 44.04 | N/A | $20.26 | $0.46 |
| 2016 | N/A | N/A | $9.88 | -$0.81 |
| 2015 | N/A | N/A | $17.33 | -$0.25 |
| 2014 | N/A | N/A | $9.65 | -$0.56 |
| 2013 | N/A | N/A | $14.99 | -$0.74 |
| 2012 | N/A | N/A | $6.71 | -$0.48 |
| 2011 | N/A | N/A | $9.51 | -$0.19 |
Halozyme Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 21.83 | -14.36% | $64.63 | $2.96 |
| Dec 2025 | 25.49 | 69.93% | $67.3 | $2.64 |
| Sep 2025 | 15 | 29.2% | $73.34 | $4.89 |
| Jun 2025 | 11.61 | -29.93% | $52.02 | $4.48 |
| Mar 2025 | 16.57 | 21.3% | $63.81 | $3.85 |
| Dec 2024 | 13.66 | -26.72% | $47.81 | $3.5 |
| Sep 2024 | 18.64 | -7.08% | $57.24 | $3.07 |
| Jun 2024 | 20.06 | 20.84% | $52.36 | $2.61 |
| Mar 2024 | 16.6 | -4.32% | $40.68 | $2.45 |
| Dec 2023 | 17.35 | -13.25% | $36.96 | $2.13 |
| Sep 2023 | 20 | -3.52% | $38.2 | $1.91 |
| Jun 2023 | 20.73 | -27.8% | $36.07 | $1.74 |
| Mar 2023 | 28.71 | -25.33% | $38.19 | $1.33 |
| Dec 2022 | 38.45 | 47.83% | $56.9 | $1.48 |
| Sep 2022 | 26.01 | 53.72% | $39.54 | $1.52 |
HALO Price vs fair value
HALO average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
The current PE ratio of HALO is above its 3 and 5-year averages, but it is under its 10-year average.
PE comparison
With a price to earnings (P/E) of 25.71, HALO stands higher than the industry average but lower than the Healthcare sector average. But when looking at the Healthcare sector average of 25.82, Halozyme Therapeutics's price to earnings (P/E) is only 0.4% lower.
HALO PE vs peers
HALO's PE ratio is less than its peer stocks LLY and JNJ, but it is above PFE's.
| Stock name | PE ratio | Market cap |
|---|---|---|
| PFE Pfizer Inc | 18.52 | $138.27B |
| HALO Halozyme Therapeutics Inc | 25.38 | $8.91B |
| JNJ Johnson & Johnson | 29.02 | $609.83B |
| LLY ELI LILLY & Co | 41.05 | $1.09T |
| MNKD Mannkind Corp | N/A | $1.23B |
| BAX Baxter International Inc | N/A | $11.19B |
Frequently asked questions
What is Halozyme Therapeutics's PE ratio?
As of Jul 13, 2026, HALO stock has a price to earnings ratio of 25.71.
What is the 3-year average PE ratio for Halozyme Therapeutics (HALO)?
Over the last 3 years, the average PE ratio for HALO stock is 17.89.
What is the 5-year average PE ratio for Halozyme Therapeutics (HALO)?
Over the last 5 years, the average PE ratio for HALO stock is 19.4.
What is the highest PE ratio for HALO?
Over the last nine years, the quarterly PE ratio reached its highest level at 146 in the Sep 2020 quarter.
How does the current PE ratio for HALO compare to its historical average?
HALO's current price to earnings ratio is 11% below its 9-year historical average.
How is HALO's PE ratio calculated (Halozyme Therapeutics PE ratio formula)?
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Jul 13, 2026), Halozyme Therapeutics's share price is $76.11. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $2.96. Therefore, Halozyme Therapeutics's price to earnings ratio for today is 25.71. PE RATIO(25.71) = STOCK PRICE($76.11) / TTM EPS($2.96)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.